Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9707MR)

This product GTTS-WQ9707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9519MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ14554MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ5161MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14409MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ8424MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ12928MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ11732MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ1373MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW